AIM ImmunoTech is focusing on reducing Ampligen production costs through manufacturing efficiencies. Progress is positive in pancreatic cancer trials, moving to Phase II soon. The ovarian cancer trial is downsizing due to impressive response rates. Financial challenges include disputes over accounts payable and insurance coverage.